B
Bellerophon Therapeutics
Bellerophon focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary diseases
About Bellerophon Therapeutics
Bellerophon Therapeutics, established in 2009 and spun out from Ikaria in 2014, is a clinical-stage biotherapeutics company. The company was incorporated as Ikaria Development LLC in October 2013 and changed its name to Bellerophon Therapeutics, Inc. in January 2014. It went public in February 2015. The firm operates at the intersection of pharmaceuticals and medical devices, concentrating on developing treatments for cardiopulmonary diseases.
The company's core focus is its proprietary INOpulse® program, a portable drug-device system designed to deliver pulsatile nitric oxide. This system administers targeted doses of nitric oxide, a vasodilator that relaxes blood vessels in the lungs, with the aim of improving blood flow and gas exchange. A key feature is the device's ability to autonomously adjust to a patient's breathing patterns, ensuring precise and consistent drug delivery. This portable, battery-powered design allows for ambulatory use, enabling patients to maintain their daily activities.
Bellerophon's primary market is patients with various forms of pulmonary hypertension (PH), a condition characterized by high blood pressure in the lung arteries. The INOpulse system has been under development for several indications, including PH associated with fibrotic interstitial lung disease (fILD), chronic obstructive pulmonary disease (PH-COPD), and sarcoidosis. The business model is typical of a clinical-stage biotherapeutics firm, centered on advancing product candidates through rigorous clinical trials to gain regulatory approval from bodies like the U.S. Food and Drug Administration (FDA) for commercialization. In March 2020, the FDA granted emergency expanded access for the INOpulse system to treat COVID-19 patients. However, a pivotal Phase 3 REBUILD trial for fILD did not meet its primary endpoint in June 2023. Following a review of strategic options, the company's board approved a plan of liquidation and dissolution in October 2023, subject to stockholder approval, and its shares were subsequently delisted from the Nasdaq Capital Market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
News
Open roles
Bellerophon Therapeutics in the Warren Township ecosystem
The Bellerophon Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
New Mountain Capital
Venrock
5AM Ventures
Aravis Ventures
ARCH Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bellerophon Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bellerophon Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

